Mode of Action and Synergy of Ceftazidime and Baicalein against *Streptococcus pyogenes*

Supatcharee Siriwong¹, Thippawan Pimchan², Wanatkamon Naknarong¹ and Griangsak Eumkeb¹*

¹School of Pharmacology, ²School of Biology, Institute of Science, Suranaree University of Technology, 111 University Avenue, Suranaree Subdistrict, Muang District, Nakhonratchasima 30000, Thailand

*For correspondence: Email: griang@sut.ac.th; Tel: +66 44 224260; Fax: +66 44 224650

Received: 12 January 2015 Revised accepted: 26 March 2015

Abstract

**Purpose:** To investigate the antibacterial activity of baicalein used alone, or in combination with ceftazidime, against *Streptococcus pyogenes*.  
**Methods:** Minimum inhibitory concentration (MIC), checkerboard assay parameters, and viability curves were determined for *S. pyogenes* DMST 30653, 30654, and 30655. Cytoplasmic membrane (CM) permeability technique, enzyme assays, transmission electron microscopy and Fourier transform-infrared microspectroscopy were used to investigate the changes in the bacterial biomolecules.  
**Results:** The MIC of ceftazidime and baicalein against all the *S. pyogenes* strains were 0.50 and > 256.0 µg/ml, respectively. A synergistic effect against these strains was exhibited by the ceftazidime/baicalein combination (fractional inhibitory concentration index, < 0.37). The results for the viable counts indicate that this synergistic activity was present. Baicalein exerted inhibitory activity against β-lactamase. Compared with the controls, combining baicalein with ceftazidime caused peptidoglycan and morphological damage, significantly increased CM permeability and protein concentrations, and decreased cellular fatty acid and nucleic acid concentrations.  
**Conclusion:** Baicalein is a potential synergistic adjunct to ceftazidime for the treatment of *S. pyogenes* infections.

**Keywords:** *Streptococcus pyogenes*, Cytoplasmic membrane permeability, Baicalein, Ceftazidime, Synergistic activity, Fourier Transform-infrared microspectroscopy, Transmission electron microscopy

INTRODUCTION

*Streptococcus pyogenes* (*S. pyogenes*), group A streptococcus, is the most common cause of bacterial pharyngitis, scarlet fever, and impetigo. *S. pyogenes* is also the group mostly associated with streptococcal toxic shock syndrome [1]. In the past two decades, increases in severe *S. pyogenes* diseases have been reported worldwide [2]. Recommended therapies for *S. pyogenes* infections include the use of penicillins and cephalosporin. However, the failure of penicillin to eradicate streptococci from the throat occurs in up to 35% of patients with pharyngeal tonsillitis [3].

Previous research results indicate that 1.9% of *S. pyogenes* infections exhibit intermediate resistance to ampicillin [4]. Khan and co-worker found *S. pyogenes* resistant to cloxacillin, oxacillin, and cefoperazone [5]. The only two described *S. pyogenes* strains are β-lactamase producers, and bla-TEM has been detected and amplified on genomic DNA of 28 β-lactam
resistant isolates from 42 S. pyogenes infections from Mansoura university hospitals [6].

Co-existing oropharyngeal beta-lactamase-producing bacteria (BLPB) may not only have survived penicillin therapy, but also could have protected other penicillin-susceptible bacteria from penicillin. Increased failure rates for penicillin used for treatment of otitis, sinusitis, and pharyngeal-tonsillitis infections associated with these bacteria have been reported [7]. Effective antibiotics available for the treatment of S. pyogenes and coexisting BLPB infections are frequently associated with β-lactam failure and unwanted side effects. Discovery of new combination agents to treat these bacteria, overcome β-lactam failures during S. pyogenes treatment and the resurgence of BLPB infections, and reduce adverse drug effects, is urgently needed. Many flavonoids isolated from plants have shown synergistic antibacterial activity [8].

The aim of the present study was to investigate the antibacterial and synergistic activities of baicalein, alone and in combination with ceftazidime, against S. pyogenes. The basic mechanism of action was also examined.

EXPERIMENTAL

Materials and bacterial strains

Streptococcus pyogenes DMST 30653, 30654, and 30655 were obtained from the Department of Medical Sciences, Ministry of Public Health, Thailand. Staphylococcus aureus ATCC 29213 (S. aureus) was purchased from the American Type Culture Collection (ATCC; Virginia, USA), and was used as a positive control. Baicalein (purity 98 %) was purchased from the Indofine Chemical Company (New Jersey, USA). Ceftazidime, amoxicillin, penicillin, β-lactamase type IV, dimethylsulfoxide, glutaraldehyde (grade I, 25 %; for electron microscopy (EM)), osmium tetroxide (4 %; for EM), a Spurr Low-Viscosity Embedding Kit, and nisin (from Lactococcus lactis, 2.5 %, balanced sodium chloride and denatured milk solids) were obtained from Sigma (Sigma-Aldrich, Dorset, UK). Mueller–Hinton agar (MHA), Mueller–Hinton broth with sheep blood (5 % v/v) agar (MHBSB), cation-adjusted Mueller–Hinton broth (CAMBH), and cation-adjusted Mueller–Hinton broth with lysed horse blood (2.5 % v/v) (CAMHBHB) were obtained from Oxoid (Basingstoke, UK).

Bacterial suspension standard curve

The bacterial suspensions standard curve method was used to determine known viable counts, following the method of Richards and Xing with few modifications [9]. Viable counts for each absorbance reading were determined in triplicate using an agar plate counting method [8,10].

Minimum inhibitory concentration (MIC)

MIC determinations of ceftazidime, amoxicillin, penicillin, nisin, and baicalein against the S. pyogenes and S. aureus strains were performed using previously reported methods [8,10,11]. Briefly, in addition to an antibacterial or baicalein, an inoculum of 5 x 10^6 cfu/ml bacterial suspension was added to each tube containing CAMHBHB (for S. pyogenes) or CAMBH (for S. aureus), to result in approximately 5 x 10^5 cfu/ml per tube. The MIC determination was accomplished by observing turbidity after 20 h of incubation at 35 °C.

Checkerboard assay

Checkerboard assays to determine the synergistic activity of baicalein in combination with ceftazidime against all tested S. pyogenes strains were performed following Eumkeb et al [8]. The interaction between the two agents was calculated using the fractional inhibitory concentration index (FICI) [12]. The FICI categories were: synergistic (FICI, ≤ 0.5), partially synergistic (FICI, > 0.5 and < 1.0), additive (FICI, 1.0), indifferent (FICI, > 1 and ≤ 4.0), and antagonistic (FICI, > 4.0). Staphylococcus aureus was used as positive control.

Determination of viability curves

Killing curve determination was performed to confirm the synergistic activity of the combination following the methods of Richards and Xing, Eumkeb et al, and the Clinical and Laboratory Standards Institute, with slight modifications [8,9,11]. After the FIC index was obtained, the MIC of each compound that was associated with the synergism FIC index for the combination was determined from the checkerboard assay, with slight modifications [9,13,14]. Shortly after the FIC index was determined from the checkerboard assay,
the half-MIC values for ceftazidime and baicalein alone, and the 3/4 MIC values for these combinations that resulted in synergistic FIC indices, were selected against S. pyogenes to measure CM permeability. This method was performed by measuring the release of UV-absorbing material (Varian's Cary 100 UV-Vis spectrophotometer, Varian, Inc, California, USA) [15].

Enzyme assay

The β-lactamase type IV of Enterobacter cloacae inhibition activity was previously described by Reading and Farmer [16]. The analyses of the remaining substrates were performed using reverse-phase HPLC with an acetonitrile/ammonium acetate mobile phase [16].

Transmission electron microscopy (TEM)

Cellular damage of the bacteria was examined using TEM. Briefly, after the FIC index was obtained from checkerboard assay, the half-MIC values for ceftazidime and baicalein alone, and the 3/4 MICs for the combinations that gave synergistic FIC indices, were chosen against S. pyogenes to investigate the morphological appearance. Subcultures were prepared for examination using TEM, based the method of Eumkeb et al [8].

Fourier Transform-Infrared (FT-IR) microspectroscopy

FT-IR measurement was performed following the methods of Eboigbodin and Biggs, and Toubas et al [17,18]. Briefly, after the FIC index was illustrated from the checkerboard assay, the half-MIC for ceftazidime alone and the 0.75 MIC for the combination that gave a synergistic FIC index against S. pyogenes were used in FT-IR studies [17-19]. The cells were incubated at 37 °C in a shaking water bath for 4 h. The cell pellets were centrifuged at 3000 x g for 10 min and washed twice with saline. The cells were then washed twice with Milli-Q water. A small portion of pellet was then deposited into a Mirr IR low e-microscope slide (Kevey slide) to use as a substrate for FT-IR microscope analysis. The cells were then desiccated under a vacuum for approximately 20 min and stored in desiccators to form acceptable films before analysis. To achieve high S/N ratios, 64 scans were coded for each measurement in the wavenumber between 4000 and 400 cm\(^{-1}\) resolution of 6 cm\(^{-1}\). Spectra were recorded in reflection mode on a Bruker IR spectrometer (Tensor 27, Massachusetts, USA) coupled to an IR microscope (Hyperion 2000, Bruker) with 36x magnification. The data for the effects of variation of the composition and distribution of the biochemical components in the bacterial cells during cell culture were analyzed using principal components analysis (PCA). All data analysis was performed in the 3000 – 2800 cm\(^{-1}\) and 1800 – 850 cm\(^{-1}\) spectral ranges, which include the fingerprint region.

Statistical analysis

All experiments were carried out in triplicate; results were expressed as mean ± standard error of the mean (SEM). Significant differences in CM permeability, the enzyme assay data between each treated group at the same interval times, and the peak area in each group of FT-IR range were analyzed using one-way ANOVA. A 0-value < 0.01, based on Scheffe's post-hoc test, was considered to indicate a statistically significant result.

RESULTS

MIC and FIC

The MIC results for ceftazidime, nisin, and baicalein against S. pyogenes tested strains are presented in Table 1. The results revealed that the MICs for ceftazidime, nisin, and baicalein against all S. pyogenes strains were 0.50, 1.0, and > 256 µg/ml, respectively. These results indicated that these strains were sensitive to ceftazidime [11]. Staphylococcus aureus ATCC 29213, a positive control, was susceptible to amoxicillin and penicillin [11]. Baicalein exhibited little inhibitory effect against this strain. The FIC indices for ceftazidime plus baicalein against all S. pyogenes strains were < 0.37. These results indicated that these combinations showed synergistic activity against this strain.

Killing curves

The results for the separate and combined effects of ceftazidime and baicalein on viable counts of S. pyogenes 30653 are presented in Figure 1. The viable counts for the cells treated with ceftazidime were slightly lower than that of baicalein (between 2 and 24 h). The combination of ceftazidime and baicalein dramatically decreased the cell count to 6 x 10\(^3\) cfu/ml after 6 h and up to 24 h.

Trop J Pharm Res, April 2015; 14(4): 643
Table 1: Minimum inhibitory concentrations (MICs), fractional inhibitory concentrations (FICs), and FIC indices for ceftazidime, amoxicillin, penicillin, nisin, and baicalein, alone or in combination, against *S. pyogenes* strains

| Strain                      | MIC (µg/ml) | FIC (µg/ml) | FIC index |
|-----------------------------|-------------|-------------|-----------|
| *S. pyogenes* DMST 30653    | 0.50        | N/D         |           |
| *S. pyogenes* DMST 30654    | 0.50        | N/D         |           |
| *S. pyogenes* DMST 30655    | 0.50        | N/D         |           |
| *S. aureus* ATCC 29213*     | N/D         | <0.2<sup>a</sup> | <0.1<sup>a</sup> |

*S. aureus* ATCC 29213, amoxicillin and penicillin were used as positive control; cef = ceftazidime, amo = amoxicillin, pen = penicillin, nis = nisin, bai = baicalein; <sup>a</sup> = susceptible; N/D = No data; n = 3

These results were confirmed by the checkerboard assay results, which indicated that the combination produced a decrease of ≥ 2 log<sub>10</sub> cfu/ml, compared with ceftazidime treatment alone [20].

The CM permeability was measured by examining the release of UV-absorbing materials (Figure 2). After treatment, *S. pyogenes* 30653 cells with nisin, ceftazidime, and the ceftazidime plus baicalein combination could induce the release of 260 nm absorbing materials at significantly higher levels compared with the control or baicalein alone (*p* < 0.01). The CM permeability strength was nisin > ceftazidime plus baicalein > ceftazidime > baicalein > control (*p* < 0.01). These results suggested that the synergistic activity of ceftazidime plus baicalein mostly resulted in increased cytoplasmic membrane permeability of DNA, RNA, and cellular metabolites [13,14].

**Enzyme assay**

The enzyme assay results for the baicalein treatment revealed that the levels of benzylpenicillin were significantly higher compared with the controls (*p* < 0.01). The levels of benzylpenicillin depended on the baicalein concentration in a decreasing, dose-dependent manner (*p* < 0.01).
TEM

The transmission electron micrographs of cells from the log phase of growth of *S. pyogenes* 30653 in the presence of ceftazidime, baicalein, and ceftazidime + baicalein are presented in Figure 3. The peptidoglycan and cytoplasmic membranes could be distinguished, and the cells had the normal appearance of the control group (Figure 3a). The micrographs of the *S. pyogenes* 30653 cells treated with ceftazidime or baicalein alone revealed that cell division may have been interrupted, which resulted in cell shape distortions (Figure 3b and 3c). The results for the combination-treated cells also indicated that cell division in many of these cells may have been interrupted, leading to twisted and irregular cell shapes, and peptidoglycan and cytoplasmic membrane damage (Figure 3d). The average areas of these cells were significantly larger compared with the control cells (*p* < 0.01).

FT-IR spectra

The 3-dimensional PCA clustering results from the FT-IR spectral data for *S. pyogenes* 30653 after treatment with ceftazidime alone and in combination with baicalein are presented in Figure 4a. The biomolecule fingerprint clusters for the control and the ceftazidime alone or in combination with baicalein groups were clearly differentiated [23,27].

The *S. pyogenes* 30653 strain was grown in CAMHBH medium in the presence of ceftazidime or the ceftazidime plus baicalein combination, and examined using FT-IR microspectroscopy. The results for the loading plots are presented in Figure 4b. The signal intensities and peak areas of these treated cells at ~1655 and ~1637 cm$^{-1}$ were ceftazidime plus baicalein > ceftazidime > control, which corresponded to an absorption peak for the secondary structure of protein amide I (α-helix and β-sheet). The peak intensity pattern for the areas at ~1085 cm$^{-1}$ was ceftazidime > control > ceftazidime plus baicalein, which correlated with an absorption peak for a nucleic acid (DNA and RNA) phosphoryl backbone (Figure 4c) [23,24].

![TEM images](image-url)

*Figure 3:* Ultrathin sections of log phase *S. pyogenes* DMST 30653 grown in cation-adjusted Mueller-Hinton broth with lysed horse blood (2.5 %v/v) containing: a, control (drug-free); b, ceftazidime, 0.25 μg/ml; c, baicalein, 128 μg/ml; d, ceftazidime, 0.09 μg/ml, plus baicalein, 24 μg/ml. (a, 195,000x, bar 500 nm; b, 7,000x, bar 1 μm; c, 19,500x, bar 500 nm; d, 7,000x, bar 1 μm; Inset: a, 26,000x, bar 200 nm; b, 19,500x, bar 500 nm; c, 19,500x, bar, 500 nm; d, 19,500x, bar, 500 nm)
The second loading of the treated and control groups indicated that the obvious regions at 3000–2800 cm\(^{-1}\) (~2963, ~2921, ~2875, ~2852 cm\(^{-1}\)) could be attributed to the stretching modes of CH\(_2\) and CH\(_3\) in the fatty acids located on the various membrane amphiphiles and ester bands, respectively (Figure 4d) [25,26]. The treated cells exhibited a peak area and intensity at ~2921 and ~2852 cm\(^{-1}\), respectively, of ceftazidime > control > ceftazidime plus baicalein (Figure 4d) [23, 27].

**DISCUSSION**

The presence of BLPB after treatment indicated that the bacteria may not only have survived penicillin therapy, but also could have protected other penicillin-susceptible bacteria from the drug and led to the failure of penicillin to eradicate this strain from the patients with pharyngeal-tonsillitis [28]. A novel antibacterial combination that can conquer \(\beta\)-lactam failures for treatment of *S. pyogenes* and the coexistence of the BLPB infections is urgently required. The MIC results revealed that all of the *S. pyogenes* strains were still sensitive to ceftazidime alone. The standard values for the sensitivities of cefotaxime (also a third-generation cephalosporin) against these strains are \(\leq 0.50\ \mu\text{g/ml}\) [11].

The checkerboard assay revealed that there were synergistic effects against all *S. pyogenes*
strains when ceftazidime was combined with baicalein (FIC index < 0.37) [12]. The killing curve result (≥ 2 log10 cfu/ml reduction) also confirmed the synergistic effect of ceftazidime plus baicalein, compared with ceftazidime alone [20].

The CM permeability results indicated that the ceftazidime plus baicalein combination clearly increased CM permeability of S. pyogenes. To our knowledge, this study is the first to reveal this effect. An increase in CM permeability may be one of the synergistic actions of this combination against S. pyogenes. These findings provide evidence that the phospholipid bilayer in the cytoplasmic membrane might have been destroyed, with a resultant leak in the plasma membrane [14].

The enzyme assay revealed that baicalein had an inhibitory activity against β-lactamase. Whether S. pyogenes produces beta-lactamase or not, a previous study found that the beta-lactamase produced by other bacteria in the pharynx can inactivate penicillin, which can result in increased treatment failures or infection relapses [29]. These findings provide evidence that baicalein in combination with beta-lactam antibiotics may useful for the inhibition of the coexistence of the BLPB and S. pyogenes in oropharyngeal infections.

The TEM results for the changes in the S. pyogenes cells after exposure to ceftazidime plus baicalein indicated that the division of many of the bacterial cells may have been interrupted. This effect likely led to the twisted and irregular cell shapes, the peptidoglycan and cytoplasmic membrane damage, and the significant increase in average cell area (p < 0.01). These results can be explained by assuming that baicalein may interact synergistically with ceftazidime to inhibit peptidoglycan synthesis. This synergistic effect can result in marked morphological damage and delayed cell division.

Our FT-IR results indicated that compared to the controls, S. pyogenes cells treated with baicalein in combination with ceftazidime had increased the α-helical and β-pleated sheet structures of amide I, but had decreased nucleic acids and fatty acid content in the bacterial cells [24]. These results suggested that this combination may damage the composition of the fatty acid chains on the phospholipid bilayer of the plasma membrane and interrupt peptidoglycan synthesis. The amide I transformation results in CM damage and increased permeability, DNA and RNA leakage, and amide I protein accumulation within the cells.

CONCLUSION

This study provided evidence that baicalein and ceftazidime have a synergistic effect against S. pyogenes. To our knowledge, this is the first report on the mechanisms of synergistic action of baicalein and ceftazidime against this strain using FT-IR. The modes of actions of this combination included inhibition of peptidoglycan synthesis, increased CM permeability and enhanced amino acid accumulation, but reduced fatty acid and nucleic acid quantities, in the bacterial cells. Because baicalein has limited toxicity, it can potentially be used as an adjunct to ceftazidime for the treatment of coexisting BLPB and S. pyogenes infections. Future studies are required to confirm that this synergism occurs in humans, and in animal species.

ACKNOWLEDGEMENT

The authors are indebted to Thailand Research Fund for funding support through the Royal Golden Jubilee Ph.D. Program (Grant no. PHD/0023/2554) as well as to Dr Kanjana Thumanu and Synchrotron Light Research Institute, Thailand, for assistance with FT-IR microspectroscopy.

REFERENCES

1. Wong SSY, Yuen K-Y. Streptococcus pyogenes and re-emergence of scarlet fever as a public health problem. Emerg Microbes Infect 2012; 1: e2.
2. Lamagni TL, Darenberg J, Luca-Harari B, Stijlender T, Efstratiou A, Henriques-Nornmark B, Vuopio-Varkila J, Bouvet A, Creli R, Ekelund K et al. Epidemiology of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol 2008; 46: 2359-2367.
3. Passali D, Lauriello M, Passali GC, Passali FM, Bellussi L. Group A streptococcus and its antibiotic resistance. Acta Otorhinolaryngol Ital 2007; 27: 27-32.
4. Gur D, Ozalp M, Sumerkan B, Kaygusuz A, Toreci K, Koksal I, Over U, Soyletir G. Prevalence of antimicrobial resistance in Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis and Streptococcus pyogenes: results of a multicentre study in Turkey. Int J Antimicrob Agents 2002; 19: 207-211.
5. Khan I, Ullah H, Ahmad S, Muhammad, Saqib, Nisa S, Irshad M, Idrees M, Saeed A. Susceptibility Of Streptococcus Pyogenes Against Various Antibiotics. App Sci Report 2013; 4: 181-183.
6. Hassan R, Barwa R, Shehata HR. Antimicrobial Resistance Genes and Some Virulence Factors in Escherichia coli and Streptococcus pyogenes.
Isolated from Mansoura University Hospitals. Egypt J Med Microbiol 2010; 19: 27-39.

7. Brook I. Cephalosporins in overcoming beta-lactamase-producing bacteria and preservation of the interfering bacteria in the treatment of otitis, sinusitis and tonsillitis. Expert Rev Anti Infect Ther 2007; 5: 939-950.

8. Eumkeb G, Sakdarat S, Siriwong S. Reversing beta-lactam antibiotic resistance of Staphylococcus aureus with galangin from Alpinia officinarum Hance and synergism with ceftazidime. Phytomedicine 2010; 18: 40-45.

9. Richards RM, Xing DK. In vitro evaluation of the antimicrobial activities of selected lozenges. J Pharm Sci 1993; 82: 1218-1220.

10. Liu IX, Durham DG, Richards RM. Baicalin synergy with beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus and other beta-lactam-resistant strains of S. aureus. J Pharm Pharmacol 2000; 52: 361-366.

11. Clinical Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. In: Matthew AW, Franklin RC, Williams AC, Micheal ND, George ME, David WH et al., editors. Clinical and Laboratory Standards Institute document M7-A7 Vol 29. 9th ed. Pennsylvania: Clinical and Laboratory Standards Institute; 2013. p. 16-34.

12. Marques MB, Brookings ES, Moser SA, Sonke PB, Waites KB. Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations. Antimicrob Agents Chemother 1997; 41: 881-885.

13. Shen L, Liu D, Li M, Jin F, Din M, Parnell LD, Lai CO. Mechanism of action of recombinant acc-royalisin from royal jelly of Asian honeybee against gram-positive bacteria. PLoS One 2012; 7: e47194.

14. Zhou K, Zhou W, Li P, Liu G, Zhang J, Dai Y. Mode of action of penicillin 31-I: An antiilisteria bacteriocin produced by Lactobacillus pentosus from Chinese traditional ham. Food Control 2008; 19: 817-822.

15. Eumkeb G, Siriwong S, Thuman K. Synergistic activity of tuteolin and amoxicillin combination against amoxicillin-resistant Escherichia coli and mode of action. J Photochem Photobiol B 2012; 117: 247-253.

16. Reading C, Farmer T. Antibiotic. In:Russell AD, Quesnel LB, editors. Assessment of antimicrobial activity and resistance. London: Academic Press; 1983. p. 141-159.

17. Eboigbodin KE, Biggs CA. Characterization of the extracellular polymeric substances produced by Escherichia coli using infrared spectroscopic, proteomic, and aggregation studies. Biomacromolecules 2008; 9: 686-695.

18. Toubas D, Essendouib M, Adt I, Pinon JM, Manfait M, Sockalingum GD. FTIR spectroscopy in medical mycology: applications to the differentiation and typing of Candida. Anal Bioanal Chem 2007; 387: 1729-1737.

19. Helm D, Naumann D. Identification of some bacterial cell components by FT-IR spectroscopy. FEMS Microbiol Lett 1995; 126: 75-79.

20. Eliopoulos GM, Moellinger RC. Antimicrobial combinations. In: Eliopoulos GM, Moellinger RC, editors. Antibiotic in Laboratory Medicine. 4th ed. Baltimore, MD: Williams and Wilkins; 1996; pp 330-396.

21. Boon RJ, Beale AS. Response of Streptococcus pyogenes to therapy with amoxicillin or amoxicillin-clavulanic acid in a mouse model of mixed infection caused by Staphylococcus aureus and Streptococcus pyogenes. Antimicrob Agents Chemother 1987; 31: 1204-1209.

22. Brook I. The role of beta-lactamase-producing bacteria in mixed infections. BMC Infect Dis 2009; 9: 202.

23. Kansiz M, Hераud P, Wood B, Burden F, Beardall J, McNaughton D. Fourier Transform infrared microscopy for rapid comparative analysis of Bacillus and Micrococcus isolates. Food Control 2006; 54: 305-319.

24. Beekes M, Lasch P, Naumann D. Analytical applications of Fourier transform-infrared (FT-IR) spectroscopy in microbiology and prion research. Vet Microbiol 2007; 123: 305-319.

25. Naumann D. Infrared spectroscopy in microbiology. In: Myers RA., Ed. Encyclopedia of Analytical Chemistry. Chichester: John Wiley & Sons; 2000; pp 102-131.

26. Garip S, Gozen AC, Severcan F. Use of Fourier transform infrared spectroscopy for rapid comparative analysis of Bacillus and Micrococcus isolates. Food Chem 2009; 113: 1301-1307.

27. Al-Qadiri HM, Al-Holy MA, Lin M, Alamh NI, Cavinato AG, Rasco B. Rapid detection and identification of Pseudomonas aeruginosa and Escherichia coli as pure and mixed cultures in bottled drinking water using Fourier transform infrared spectroscopy and multivariate analysis. J Agric Food Chem 2006; 54: 5479-5574.

28. Brook I. Overcoming penicillin failures in the treatment of Group A streptococcal pharyngo-tonsillitis. Int J Pediatr Otorhinolaryngol 2007; 71: 1501-1508.

29. Reed BD, Huck W, Zazove P. Treatment of beta-hemolytic streptococcal pharyngitis with cefadroxil or penicillin. Efficacy and interaction with beta-lactamase-producing organisms in the pharynx. J Fam Pract 1991; 32: 138-144.